Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

In vivo purging and relapse prevention following ASCT

Bone Marrow Transplantation volume 29, pages S5–S9 (2002)Cite this article

Abstract

The combination of high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL) and is increasingly being considered as a first-line treatment for NHL patients with poor prognosis or poor outcomes from chemotherapy. However, there is a degree of relapse following the latter which is associated with high levels of tumour cell contamination of the stem cells and/or the presence of residual malignant cells in the host following chemotherapy. Reducing the rate of relapse can be achieved by pre-transplant purging of the stem cell graft followed by post-transplant maintenance to minimise residual disease. Various methods of in vitro purging have been shown to reduce, but not eliminate, the level of stem cell contamination and invariably result in a reduced harvest. To date, this has been reflected in disappointing outcomes for the patient. In contrast, in vivo purging with rituximab during the process of stem cell mobilisation and collection does not adversely affect the yield or function of stem cells and shows a significant improvement in the level of tumour cell contamination as measured by bcl-2 clearance. The relapse potential from residual malignant cells in the host can be addressed by a programme of post-transplant rituximab maintenance therapy. In one study 17 patients with follicular lymphoma who underwent ASCT with in vivo rituximab-purged stem cells, followed by rituximab maintenance, have all remained in complete response at a median follow-up of 12.4 months. The optimum in vivo rituximab purging protocol and the precise effect in terms of overall and disease-free survival are currently being evaluated but appear to present an attractive first-line alternative for NHL patients with poor prognosis or poor outcomes following chemotherapy.

Bone Marrow Transplantation (2002) 29, Suppl. 1, S5–S9. doi:10.1038/sj.bmt.1703295

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540 1545

    Article  CAS  PubMed  Google Scholar 

  2. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma Blood 1995 86: 3257 3262

    CAS  PubMed  Google Scholar 

  3. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma J Clin Oncol 1997 15: 445 450

    Article  CAS  PubMed  Google Scholar 

  4. Jacquy C, Soree A, Lambert F et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells Br J Haematol 2000 110: 631 637

    Article  CAS  PubMed  Google Scholar 

  5. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275 3280

    CAS  PubMed  Google Scholar 

  6. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 1993 81: 3449 3457

    CAS  PubMed  Google Scholar 

  7. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325 3333

    CAS  PubMed  Google Scholar 

  8. Yerly-Motta V, Racadot E, Fest T et al. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells Leuk Lymphoma 1996 23: 313 321

    Article  CAS  PubMed  Google Scholar 

  9. Martin-Henao GA, Picon M, Limon A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL) Bone Marrow Transplant 1999 23: 579 587

    Article  CAS  PubMed  Google Scholar 

  10. Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation – results of a retrospective analysis on 120 patients autografted in a single institution J Clin Oncol 1998 16: 2803 2816

    Article  CAS  PubMed  Google Scholar 

  11. Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems Stem Cells 1997 15: 297 304

    Article  CAS  PubMed  Google Scholar 

  12. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry J Clin Oncol 1996 14: 2454 2464

    Article  CAS  PubMed  Google Scholar 

  13. Schouten HC, Kvaloy S, Sydes M et al. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL) Ann Oncol 2000 11 (Suppl. 1): 91 94

    Article  Google Scholar 

  14. Bensinger WI . Should we purge? Bone Marrow Transplant 1998 21: 113 115

    Article  CAS  PubMed  Google Scholar 

  15. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 1998 92: 1927 1932

    CAS  PubMed  Google Scholar 

  16. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825 2833

    Article  CAS  PubMed  Google Scholar 

  17. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 2001 97: 101 106

    Article  CAS  PubMed  Google Scholar 

  18. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268 276

    Article  CAS  PubMed  Google Scholar 

  19. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 200 19: 389 397

    Article  Google Scholar 

  20. Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial Blood 2000 96 (Suppl. 1): 950a

    Google Scholar 

  21. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 1994 83: 435 445

    CAS  PubMed  Google Scholar 

  22. Shan D, Ledbetter JA, Press OW . Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 1998 91: 1644 1652

    CAS  PubMed  Google Scholar 

  23. Demidem A, Hanna N, Hariharan H et al. Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins FASEB J 1995 9: A206

    Google Scholar 

  24. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biother Radiopharm 1997 12: 177 186

    Article  CAS  PubMed  Google Scholar 

  25. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 1997 10: 3266 3274

    Article  Google Scholar 

  26. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 5 (Suppl. 14): 115 122

    Google Scholar 

  27. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts) Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

  28. Haioun C, Delfau-Larue MH, Beaujean F et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin's lymphomas (NHL). A single institution study Blood 2000 96 (Suppl. 1): 384a

    Google Scholar 

  29. Goldberg SL, Pecora AL, Jennis AA et al. Rituximab permits in vivo purging and collection of tumor-free stem cells prior to autologous transplantation for B-cell non-Hodgkin's lymphoma Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

  30. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864 869

    CAS  PubMed  Google Scholar 

  31. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol 2000 109: 729 735

    Article  CAS  PubMed  Google Scholar 

  32. Horwitz SM, Breslin S, Negrin RS et al. Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications Blood 2000 96: (Abstr. 1652) 385a

    Google Scholar 

  33. Buckstein R, Imrie K, Spaner D et al. Consolidative immunotherapy with rituxan in autologous stem cell transplantation in follicular lymphoma is associated with molecular remissions Proc Am Soc Clin Oncol 2000 19: 26a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Hôpital Saint Louis, Paris, France

    C Gisselbrecht

Authors
  1. C Gisselbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gisselbrecht, C. In vivo purging and relapse prevention following ASCT. Bone Marrow Transplant 29 (Suppl 1), S5–S9 (2002). https://doi.org/10.1038/sj.bmt.1703295

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703295

Keywords

This article is cited by

Search

Advanced search

Quick links